$GRFS

Grifols SA

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$12.95 ▼-2.485%

Delayed Price

VOLUME

244,947

DAY RANGE

-

52 WEEK

10.1 - 19.07

Join Discuss about GRFS with like-minded investors

profile
@dros #droscrew
recently

Downgrades 11/5: $BGS $BLKB $CS $CTXS $CYRX $GIL $GRFS $IBP $LEVL $NKLA $NOMD $NPTN $NVS $PPL $PTON $PYPL $PZZA $QRVO $REGN $RMNI $SSYS $SWKS $TKC $TPIC $VMEO $ZG

88 Replies 14 👍 6 🔥

Key Metrics

Market Cap

3.47 B

Beta

0.58

Avg. Volume

0.90 M

Shares Outstanding

261.43 M

Yield

3.44%

Public Float

0

Next Earnings Date

2022-07-28

Next Dividend Date

Company Information

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2019, Grifols' economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

Website:

HQ: C/ Jesus y Maria, 6 Barcelona, 08022 Barcelona

Related News